Table 1.

Study Immunization Regimens and Schedule

Group	Regimen	Subjects, No.		Month 0			Month 4
		Vaccine Group	Placebo Group	Vaccine	Route	Dosea	Vaccine	Route	Dosea
A	SLA	12	4	SeV-Gag	Intranasal	2 × 107	Ad35-GRIN	Intramuscular	1 × 1010
B	SHA	12	4	SeV-Gag	Intranasal	2 × 108	Ad35-GRIN	Intramuscular	1 × 1010
C	ASH	12	5b	Ad35-GRIN	Intramuscular	1 × 1010	SeV-Gag	Intranasal	2 × 108
D	SHSH	12	4	SeV-Gag	Intranasal	2 × 108	SeV-Gag	Intranasal	2 × 108

Abbreviations: Ad35-GRIN, adenovirus 35–vectored vaccine encoding Gag, reverse transcriptase, integrase, and Nef; AS_H, Ad35-GRIN prime followed by SeV-Gag boost; HIV-1, human immunodeficiency virus type 1; S_HA, higher-dose SeV-Gag prime and Ad35-GRIN boost; S_HS_H, higher-dose SeV-Gag prime and boost; S_LA, lower-dose SeV-Gag prime and Ad35-GRIN boost; SeV-Gag, Sendai virus–vectored vaccine encoding HIV-1 Gag.

^a Data are 1 × 10⁷ or 1 × 10⁸ cell infectious units/100 µL per nostril (for SeV-Gag) or 1 × 10¹⁰ viral particles (for Ad35-GRIN).

^b Overenrollment was allowed per protocol; one additional volunteer, identified post unblinding as a placebo recipient, was enrolled.